203 related articles for article (PubMed ID: 32094461)
1. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D; Berdeja JG; Reece D; White D; Lentzsch S; Gasparetto C; Huff CA; Jagannath S; Baz R; Nooka AK; Richter J; Abonour R; Parker TL; Yee AJ; Moreau P; Lonial S; Tuchman S; Weisel KC; Mohty M; Choquet S; Unger TJ; Li K; Chai Y; Li L; Shah J; Shacham S; Kauffman MG; Dimopoulos MA
Leukemia; 2020 Sep; 34(9):2430-2440. PubMed ID: 32094461
[TBL] [Abstract][Full Text] [Related]
2. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
3. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
[TBL] [Abstract][Full Text] [Related]
5. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Dev R; Zhong LL; Zarifa A; Albittar AA; Rubin L; Liu S; Yap TA; Dalal S; Hui D; Karp DD; Tsimberidou AM; Piha-Paul SA; Ahnert JR; Fu S; Meric-Bernstam F; Naing A
Invest New Drugs; 2022 Feb; 40(1):124-133. PubMed ID: 34559346
[TBL] [Abstract][Full Text] [Related]
6. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
7. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
10. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
12. Selinexor for the treatment of multiple myeloma.
Podar K; Shah J; Chari A; Richardson PG; Jagannath S
Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
[No Abstract] [Full Text] [Related]
13. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Gounder MM; Zer A; Tap WD; Salah S; Dickson MA; Gupta AA; Keohan ML; Loong HH; D'Angelo SP; Baker S; Condy M; Nyquist-Schultz K; Tanner L; Erinjeri JP; Jasmine FH; Friedlander S; Carlson R; Unger TJ; Saint-Martin JR; Rashal T; Ellis J; Kauffman M; Shacham S; Schwartz GK; Abdul Razak AR
J Clin Oncol; 2016 Sep; 34(26):3166-74. PubMed ID: 27458288
[TBL] [Abstract][Full Text] [Related]
14. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Machlus KR; Wu SK; Vijey P; Soussou TS; Liu ZJ; Shacham E; Unger TJ; Kashyap T; Klebanov B; Sola-Visner M; Crochiere M; Italiano JE; Landesman Y
Blood; 2017 Aug; 130(9):1132-1143. PubMed ID: 28630120
[TBL] [Abstract][Full Text] [Related]
15. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Thein KZ; Karp DD; Tsimberidou A; Gong J; Sulovic S; Shah J; Milton DR; Hong DS; Janku F; McQuinn L; Stephen BA; Colen R; Carter BW; Yap TA; Piha-Paul SA; Fu S; Meric-Bernstam F; Naing A
Invest New Drugs; 2022 Apr; 40(2):290-299. PubMed ID: 34562230
[TBL] [Abstract][Full Text] [Related]
16. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
[TBL] [Abstract][Full Text] [Related]
19. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
20. Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
Abid H; Wu JF; Abid MB
Eur J Cancer; 2021 Sep; 154():7-10. PubMed ID: 34217910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
